No Data
IRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $111
Insiders At IRhythm Technologies Sold US$8.0m In Stock, Alluding To Potential Weakness
Goldman Sachs Maintains IRhythm Technologies(IRTC.US) With Hold Rating, Raises Target Price to $91
Morgan Stanley Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $95
Strategic Growth and Expansion of Irhythm Technologies: A Promising Future in Arrhythmia Detection
IRhythm Technologies, Inc. (NASDAQ:IRTC): When Will It Breakeven?
